Alteogen Reports Completion of P-I Study of ALT-L9 (biosimilar- aflibercept) in Korea
Shots:
- The company has completed a P-I trial that assessed ALT-L9 vs Eylea in 28 patients in a ratio (1:1) with neovascular (wet) AMD. The trial was conducted at 4 major hospitals in Korea
- The safety & efficacy of ALT-L9 were similar to Eylea and the results showed similar improvement effects in BCVA and CST. The P-I results will support the design of the P-III study and provide a path to a shorter P-III trial
- Alteogen strengthens the competitiveness through global formulation and patents registration in the US- EU and Japan and filing of a process patent for PCT application
Ref: Businesswire | Image: Businesswire
Click here to read the full press release
Tags
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
